Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.

被引：0

作者：

Friedlander, Terence W.

Milowsky, Matthew I.

O'Donnell, Peter H.

Petrylak, Daniel P.

Hoimes, Christopher J.

Flaig, Thomas W.

Mar, Nataliya

Moon, Helen H.

McKay, Rana R.

Bilen, Mehmet Asim

Borchiellini, Delphine

Iafolla, Marco

Carret, Anne-Sophie

Yu, Yao

Guseva, Maria

Kataria, Ritesh S.

Rosenberg, Jonathan E.

机构：

[1] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[5] Duke Univ, Duke Canc Inst, Durham, NC USA

[6] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA

[7] Univ Calif Irvine, Irvine, CA USA

[8] Kaiser Permanente Southern Calif, Riverside, CA USA

[9] Univ Calif San Diego, San Diego, CA 92103 USA

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Univ Cote Azur, Ctr Antoine Lacassagne, Nice, France

[12] Univ Toronto, Toronto, ON, Canada

[13] Seagen Inc, Bothell, WA USA

[14] Astellas Pharma Inc, Northbrook, IL USA

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4568

引用

页数：1

共 20 条

[1] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
O'Donnell, Peter H.
Milowsky, Matthew I.
Petrylak, Daniel P.
Hoimes, Christopher J.
Flaig, Thomas W.
Mar, Nataliya
Moon, Helen H.
Friedlander, Terence W.
McKay, Rana R.
Bilen, Mehmet A.
Srinivas, Sandy
Burgess, Earle F.
Ramamurthy, Chethan
George, Saby
Geynisman, Daniel M.
Bracarda, Sergio
Borchiellini, Delphine
Geoffrois, Lionnel
Rey, Jose Pablo Maroto
Ferrario, Christiano
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
[2] Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
Rosenberg, J. E.
Milowsky, M.
Ramamurthy, C.
Mar, N.
Mckay, R. R.
Friedlander, T.
Ferrario, C.
Bracarda, S.
George, S.
Moon, H.
Geynisman, D.
Petrylak, D. P.
Borchiellini, D.
Burgess, E. F.
Rey, J. P. Maroto
Carret, A-S.
Yu, Y.
Guseva, M. V.
Moreno, B. Homet
O'Donnell, P. H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1441 - S1441
[3] Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
O'Donnell, Peter H.
Rosenberg, Jonathan E.
Hoimes, Christopher J.
Petrylak, Daniel P.
Milowsky, Matthew I.
Mckay, Rana R.
Srinivas, Sandy
Friedlander, Terence W.
Ramamurthy, Chethan
Bilen, Mehmet Asim
Burgess, Earle F.
Mar, Nataliya
Moon, Helen
Geynisman, Daniel M.
George, Saby
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Flaig, Thomas W.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[4] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
Milowsky, Matthew I.
O'Donnell, Peter H.
Hoimes, Christopher J.
Petrylak, Daniel P.
Flaig, Thomas W.
Moon, Helen H.
Friedlander, Terence W.
Mar, Nataliya
McKay, Rana R.
Srinivas, Sandy
Gravis, Gwenaelle
Ramamurthy, Chethan
Bupathi, Manojkumar
Bracarda, Sergio
Wright, Phoebe
Carret, Anne-Sophie
Yu, Yao
Matsuda, Tara
Kataria, Ritesh S.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[5] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39
Van Der Heijden, Michiel Simon
Gupta, Shilpa
Bedke, Jens
Valderrama, Begona Perez
Kikuchi, Eiji
Iyer, Gopa
Loriot, Yohann
Dawson, Nancy Ann
Hoffman-Censits, Jean H.
Mar, Nataliya
Sridhar, Srikala S.
Maroto-Rey, Pablo
Shin, Sang Joon
Yu, Evan Y.
Duran, Ignacio
Birrenkott, Matthew
Yu, Xuesong
Shetty, Aditya
Bavle, Abhishek Amar
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Rosenberg, J. E.
Flaig, T. W.
Friedlander, T. W.
Milowsky, M. I.
Srinivas, S.
Petrylak, D. P.
Merchan, J. R.
Bilen, M. A.
Carret, A. -S.
Yuan, N.
Sasse, C.
Hoimes, C. J.
SWISS MEDICAL WEEKLY, 2020, : 26S - 27S
[7] Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
Gupta, Shilpa
Rosenberg, Jonathan E.
Mckay, Rana R.
Flaig, Thomas W.
Petrylak, Daniel P.
Hoimes, Christopher J.
Friedlander, Terence W.
Bilen, Mehmet Asim
Srinivas, Sandy
Burgess, Earle F.
Merchan, Jaime R.
Tagawa, Scott T.
Brown, Jason R.
Yu, Yao
Carret, Anne-Sophie
Wirtz, Heidi
Guseva, Maria
Moreno, Blanca Homet
Milowsky, Matthew I.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39
Bedke, Jens
Van Der Heijden, Michiel Simon
Powles, Thomas
Valderrama, Begona Perez
Kikuchi, Eiji
Iyer, Gopa
Vulsteke, Christof
Swami, Umang
Castellano, Daniel
Sarwar, Naveed
Drakaki, Alexandra
Hoffman-Censits, Jean H.
Arafat, Waddah
Andabekov, Timur
Li, Jian-Ri
Lu, Yi-Tsung
Yu, Xuesong
Shetty, Aditya
Moreno, Blanca Homet
Gupta, Shilpa
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Powles, T. B.
Van der Heijden, M. S.
Gupta, S.
Perez Valderrama, B.
Galsky, M. D.
Bedke, J.
Kikuchi, E.
Hoffman-Censits, J.
Rey, J. P. Maroto
Vulsteke, C.
Iyer, G.
Swami, U.
Shin, S. J.
Rodriguez-Vida, A.
Wozniak, M.
Moreno, B. Homet
Lu, J.
Yu, C.
Hogdal, L.
Loriot, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1137 - S1138
[10] Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
Van Der Heijden, Michiel Simon
Powles, Thomas
Gupta, Shilpa
Bedke, Jens
Kikuchi, Eiji
De Wit, Ronald
Galsky, Matt D.
Duran, Ignacio
Necchi, Andrea
Retz, Margitta
Yu, Evan Y.
Hoffman-Censits, Jean H.
Iyer, Gopa
Park, Se Hoon
Su, Wen-Pin
Parmar, Hema
Guan, Xuesong
Gorla, Seema Rao
Homet Moreno, Blanca
Valderrama, Begona Perez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : LBA530 - LBA530

← 1 2 →